PHOENIX PHARMALABS, INC.
WOODS CROSS, UT · CIK 0001755778 · Biotech · Private
Pharmaceutical compounds and drug candidates (PPL-138 lead program)
phoenixpharmalabs.com →- Grants
- $507K
- 2 awards
- Sector median: 1
- Raised
- $3.5M
- 1 Form D · Nov 2018
- 95 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 7
- 0 granted · 7 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201820192020202120222023
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · The Kappa Partial Agonist PPL-103 as a Potential Cocaine Abuse Pharmacotherapy | $186,687 | |
| Private capital raised | Form D · SEC | $3,500,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Identification of Mixed NOP/mu partial agonists as lead compounds for treatment of methamphetamine use disorder | $319,983 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2075 | RGENIX, INC. | — | — |
| 2076 | Outpost Intros Inc. | — | $475K |
| 2077 | Leal Therapeutics | — | — |
| 2078 | PHOENIX PHARMALABS, INC. | — | $3.5M |
| 2079 | STEMCELLLIFE LLC | — | — |
| 2080 | Synergyan, LLC | — | — |
| 2081 | Rhino Health Inc. | — | $7.0M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Timmy ChouDirector · Executive Officer · Promoter
- William CrossmanDirector · Executive Officer · Promoter
- John LawsonDirector · Executive Officer · Promoter
- Chris TewDirector · Executive Officer · Promoter
- Lawrence TollDirector · Executive Officer · Promoter
Patents
- Use Of Morphinans For Treating Cocaine Addiction, Pruritis, And Seizure Disordersapplication
- Use Of Morphinans For Treating Cocaine Addiction, Pruritis, And Seizure Disordersapplication
- Use Of Morphinans For Treating Cocaine Addiction, Pruritis, And Seizure Disordersapplication
- Use Of Morphine Analogs For Animal Healthapplication
- Novel Morphinans Useful As Analgesicsapplication
- Methods Of Synthesis Of Morphinansapplication
- Treatment Of Chemical Dependency With Substantially Nonaddicting Normorphine And Norcodeine Derivativesapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.